INTERVENTION 1:	Intervention	0
BBT-I + Armodafinil	Intervention	1
armodafinil	CHEBI:77590	8-19
Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.	Intervention	2
insomnia	HP:0100785	33-41
Armodafinil 150 mg/day by mouth.	Intervention	3
armodafinil	CHEBI:77590	0-11
mouth	UBERON:0000165	26-31
BBT-I: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone	Intervention	4
insomnia	HP:0100785	41-49
Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.	Intervention	5
armodafinil	CHEBI:77590	0-11
armodafinil	CHEBI:77590	30-41
mouth	UBERON:0000165	23-28
eugeroic	CHEBI:77567	77-85
modafinil	CHEBI:31859	2-11
modafinil	CHEBI:31859	32-41
modafinil	CHEBI:31859	86-95
modafinil	CHEBI:31859	162-171
r	CHEBI:8735	1-2
r	CHEBI:8735	31-32
r	CHEBI:8735	58-59
r	CHEBI:8735	81-82
r	CHEBI:8735	98-99
r	CHEBI:8735	129-130
r	CHEBI:8735	145-146
r	CHEBI:8735	154-155
INTERVENTION 2:	Intervention	6
Behavioral Placebo + Armodafinil	Intervention	7
armodafinil	CHEBI:77590	21-32
Control behavioral intervention is a sleep hygiene handout completed by participant.	Intervention	8
sleep	GO:0030431	37-42
Armodafinil 150 mg/day by mouth.	Intervention	9
armodafinil	CHEBI:77590	0-11
mouth	UBERON:0000165	26-31
Control: Control behavioral intervention is a sleep hygiene handout completed by participant.	Intervention	10
sleep	GO:0030431	46-51
Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.	Intervention	11
armodafinil	CHEBI:77590	0-11
armodafinil	CHEBI:77590	30-41
mouth	UBERON:0000165	23-28
eugeroic	CHEBI:77567	77-85
modafinil	CHEBI:31859	2-11
modafinil	CHEBI:31859	32-41
modafinil	CHEBI:31859	86-95
modafinil	CHEBI:31859	162-171
r	CHEBI:8735	1-2
r	CHEBI:8735	31-32
r	CHEBI:8735	58-59
r	CHEBI:8735	81-82
r	CHEBI:8735	98-99
r	CHEBI:8735	129-130
r	CHEBI:8735	145-146
r	CHEBI:8735	154-155
INCLUSION CRITERIA	Eligibility	0
Be scheduled for cancer treatment with chemotherapy or biologics (prior chemotherapy and/or diagnosis of metastatic breast are allowed)	Eligibility	1
cancer	DOID:162	17-23
breast	UBERON:0000310	116-122
Have at least 6 weeks of treatment remaining	Eligibility	2
21 years old	Eligibility	3
Able to understand written and spoken English	Eligibility	4
Able to swallow medication (until amendment omitting armodafinil treatment)	Eligibility	5
armodafinil	CHEBI:77590	53-64
Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI)	Eligibility	6
sleep	GO:0030431	19-24
insomnia	HP:0100785	73-81
severity	HP:0012824	82-90
EXCLUSION CRITERIA	Eligibility	7
Prior treatment with armodafinil or modafinil (until amendment omitting armodafinil treatment)	Eligibility	8
armodafinil	CHEBI:77590	21-32
armodafinil	CHEBI:77590	72-83
modafinil	CHEBI:31859	23-32
modafinil	CHEBI:31859	36-45
modafinil	CHEBI:31859	74-83
Prior treatment with psycho-stimulant medication within the past 28 days (until amendment omitting armodafinil treatment)	Eligibility	9
armodafinil	CHEBI:77590	99-110
Prior treatment with antiseizure medications (until amendment omitting armodafinil treatment)	Eligibility	10
armodafinil	CHEBI:77590	71-82
Has continuously taken sleep medication daily for the last 28 days (until amendment omitting armodafinil treatment)	Eligibility	11
sleep	GO:0030431	23-28
armodafinil	CHEBI:77590	93-104
History (self-reported) of unstable medical or psychiatric illness (within the last 5 years)	Eligibility	12
history	BFO:0000182	0-7
History of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment)	Eligibility	13
history	BFO:0000182	0-7
disease	DOID:4,OGMS:0000031	33-40
hypertension	HP:0000822,DOID:10763	42-54
severe	HP:0012828	56-62
glaucoma	HP:0000501,DOID:1686	74-82
armodafinil	CHEBI:77590	122-133
Pregnant or nursing	Eligibility	14
History of substance abuse or meet criteria for current alcohol abuse or dependence	Eligibility	15
history	BFO:0000182	0-7
substance abuse	DOID:302	11-26
alcohol	CHEBI:16236	56-63
History (self-reported) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS)	Eligibility	16
history	BFO:0000182	0-7
chronic	HP:0011010	27-34
insomnia	HP:0100785	48-56
sleep apnea	HP:0010535,DOID:0050847	58-69
leg	UBERON:0000978	83-86
syndrome	DOID:225	87-95
Severe hepatic impairment (until amendment omitting armodafinil treatment)	Eligibility	17
severe	HP:0012828	0-6
armodafinil	CHEBI:77590	52-63
Outcome Measurement:	Results	0
Insomnia Severity Index (ISI)	Results	1
insomnia	HP:0100785	0-8
severity	HP:0012824	9-17
Insomnia Severity Index (ISI) survey questionnaire is a 7-question survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. The full range of ISI scores is from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia. Clinical interpretation is as follows.	Results	2
insomnia	HP:0100785	0-8
insomnia	HP:0100785	376-384
severity	HP:0012824	9-17
mild	HP:0012825	127-131
moderate	HP:0012826	133-141
severe	HP:0012828	143-149
severe	HP:0012828	159-165
range	LABO:0000114	219-224
healthy	HP:0032322	301-308
0 to 7 No clinically significant insomnia	Results	3
insomnia	HP:0100785	33-41
8 to14 Subthreshold insomnia	Results	4
insomnia	HP:0100785	20-28
15 to 21 Clinical insomnia (moderate severity)	Results	5
insomnia	HP:0100785	18-26
moderate	HP:0012826	28-36
severity	HP:0012824	37-45
22 to 28 Clinical insomnia (severe)	Results	6
insomnia	HP:0100785	18-26
severe	HP:0012828	28-34
ISI survey was conducted at baseline, 3 weeks, 6 weeks, 10 weeks, and 32 weeks. The outcome is reported as the mean ISI score with standard deviation.	Results	7
mean	BAO:0002173	111-115
standard deviation	BAO:0002176	131-149
Time frame: up to 32 Weeks	Results	8
time	PATO:0000165	0-4
Results 1:	Results	9
Arm/Group Title: BBT-I + Armodafinil	Results	10
armodafinil	CHEBI:77590	25-36
Arm/Group Description: Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.	Results	11
insomnia	HP:0100785	56-64
Armodafinil 150 mg/day by mouth.	Results	12
armodafinil	CHEBI:77590	0-11
mouth	UBERON:0000165	26-31
BBT-I: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone	Results	13
insomnia	HP:0100785	41-49
Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.	Results	14
armodafinil	CHEBI:77590	0-11
armodafinil	CHEBI:77590	30-41
mouth	UBERON:0000165	23-28
eugeroic	CHEBI:77567	77-85
modafinil	CHEBI:31859	2-11
modafinil	CHEBI:31859	32-41
modafinil	CHEBI:31859	86-95
modafinil	CHEBI:31859	162-171
r	CHEBI:8735	1-2
r	CHEBI:8735	31-32
r	CHEBI:8735	58-59
r	CHEBI:8735	81-82
r	CHEBI:8735	98-99
r	CHEBI:8735	129-130
r	CHEBI:8735	145-146
r	CHEBI:8735	154-155
Overall Number of Participants Analyzed: 9	Results	15
Mean (Standard Deviation)	Results	16
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: units on a scale  Baseline: 9 participants	Results	17
16.3         (7.4)	Results	18
3 Weeks: 2 participants	Results	19
13.0         (7.1)	Results	20
6 Weeks: 6 participants	Results	21
9         (6.1)	Results	22
10 Weeks: 4 participants	Results	23
6.0         (3.6)	Results	24
32 Weeks: 1 participants	Results	25
3.0  [1]        (NA)	Results	26
Results 2:	Results	27
Arm/Group Title: Behavioral Placebo + Armodafinil	Results	28
armodafinil	CHEBI:77590	38-49
Arm/Group Description: Control behavioral intervention is a sleep hygiene handout completed by participant.	Results	29
sleep	GO:0030431	60-65
Armodafinil 150 mg/day by mouth.	Results	30
armodafinil	CHEBI:77590	0-11
mouth	UBERON:0000165	26-31
Control: Control behavioral intervention is a sleep hygiene handout completed by participant.	Results	31
sleep	GO:0030431	46-51
Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.	Results	32
armodafinil	CHEBI:77590	0-11
armodafinil	CHEBI:77590	30-41
mouth	UBERON:0000165	23-28
eugeroic	CHEBI:77567	77-85
modafinil	CHEBI:31859	2-11
modafinil	CHEBI:31859	32-41
modafinil	CHEBI:31859	86-95
modafinil	CHEBI:31859	162-171
r	CHEBI:8735	1-2
r	CHEBI:8735	31-32
r	CHEBI:8735	58-59
r	CHEBI:8735	81-82
r	CHEBI:8735	98-99
r	CHEBI:8735	129-130
r	CHEBI:8735	145-146
r	CHEBI:8735	154-155
Overall Number of Participants Analyzed: 9	Results	33
Mean (Standard Deviation)	Results	34
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: units on a scale  Baseline: 9 participants	Results	35
14.6         (6.3)	Results	36
3 Weeks: 9 participants	Results	37
10.8         (6.5)	Results	38
6 Weeks: 9 participants	Results	39
10         (6.9)	Results	40
10 Weeks: 9 participants	Results	41
8.3         (5.6)	Results	42
32 Weeks: 9 participants	Results	43
7.6         (4.4)	Results	44
Adverse Events 1:	Adverse Events	0
Total: 1/9 (11.11%)	Adverse Events	1
Death, not otherwise specified 0/9 (0.00%)	Adverse Events	2
death	OAE:0000632	0-5
Pain, bone 1/9 (11.11%)	Adverse Events	3
pain	HP:0012531	0-4
Adverse Events 2:	Adverse Events	4
Total: 1/9 (11.11%)	Adverse Events	5
Death, not otherwise specified 1/9 (11.11%)	Adverse Events	6
death	OAE:0000632	0-5
Pain, bone 0/9 (0.00%)	Adverse Events	7
pain	HP:0012531	0-4
